Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

2(50%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

25%

Ph early_phase_1

25%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Detailed Status

Active, not recruiting2

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (25.0%)

Phase 12 (50.0%)

Phase 21 (25.0%)

Trials by Status

active_not_recruiting250%

completed250%

Recent Activity

2 active trials

Showing 4 of 4

active_not_recruitingphase_2

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

NCT05827055

active_not_recruitingphase_1

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

NCT05551858

completedphase_1

Safety and Tolerability of Oral Proglumide for NASH

NCT04152473

completedearly_phase_1

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

NCT04814602

Clinical Trials (4)

Showing 4 of 4 trials

NCT05827055Phase 2

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Active Not Recruiting

NCT05551858Phase 1

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

Active Not Recruiting

NCT04152473Phase 1

Safety and Tolerability of Oral Proglumide for NASH

Completed

NCT04814602Early Phase 1

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4